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Purpose: The purpose of this study was to assess whether daily walking activity is indicative of
disease severity in patients with COPD.
Methods: Daily activity was measured by accelerometry in 107 COPD: GOLD II (NZ 28), GOLD
III (NZ 51), and GOLD IV (NZ 25). Steps per day and times (min/day) spent passively, actively,
walking (WLK, 0e5 km/h), and fast walking (FWLK, >5 km/h) were analyzed. Total walking
time (TWT) was computed.
Results: Times spent WLK (PZ 0.031), FWLK (PZ 0.001), TWT (PZ 0.021), and steps per
day (PZ 0.013) differed significantly between GOLD stages. There was a significant
negative correlation between TWK and GOLD stage (RZ 0.35; P< 0.0001), BODE index
(RZ 0.58; P < 0.0001), and MMRC dyspnea scale (RZ 0.65; P < 0.0001). Logistic
regression analysis showed that both TWT and FWLK were independently and significantly
associated with BODE index 6 (PZ 0.029 and PZ 0.040, respectively). The correspond-
ing AUC-value with 95% CI for TWT was 0.80 (95% CI: 0.70 to 0.90) and 0.87 (95% CI: 0.81
to 0.94) for FWLK. The corresponding optimal cut-off value for TWT was 33.3 min/day
(sensitivity: 86%; specificity 70%) and FWLK was 0.10 min/day (sensitivity: 93%; specificity
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Association of daily physical activity volume and intensity with COPD severity 1847Conclusion: Daily walking activity, in particular walking intensity, is significant predictor
of disease severity in patients with COPD. Objective measures of habitual activity might
provide additive value in assessing the likelihood of poor prognosis in this patient cohort.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Exercise capacity measured by means of 6-min walk distance
and/or peak oxygen uptake (VO2max) during cycle ergometry
is independent predictor ofmortality in patients with chronic
obstructive pulmonary disease (COPD).1e3 Depending on
disease severity, patients suffer from mild to severe airflow
limitations induced by the decline in smoking related lung
function.4 The resulting decrease in functional exercise
capacity manifests itself as breathlessness upon only mild
exertion markedly limiting quality of life.5e7
The prevalence and incidence of COPD are rapidly
increasing and a systematic reduction in disease specific
risk factors must be actively targeted, in particular tobacco
use. In addition, more awareness about short- and long-
term health benefits associated with physical activity must
be raised in terms of attenuating disease progression.8
Several systematic reviews of chronic disease manage-
ment have shown that integrated care programs with an
interdisciplinary approach and emphasis on self-
management maximize long-term patient outcome.9e11 In
this regard, regular physical activity plays an important role
in chronic disease management and has been associated
with a slower decline in smoking related lung function,
a reduction in hospital admissions and overall improvement
in survival rates among COPD patients.1 Therefore,
encouraging patients to become more physically active has
become a major focus in modern COPD therapy.12e14
The use of accelerometers to measure physical activity
levels in free living conditions is rapidly increasing in
literature and many studies have employed these devices to
investigate possible relationships between physical activity
levels and clinical outcome.6,7,15e19 Likewise, previous
investigators have demonstrated clinically useful associa-
tions between accelerometer derived activity data and
functional status in patients with COPD.4,6,7,14 Neverthe-
less, detailed analyses of accelerometer derived activity
data in terms of activity mode, duration, frequency and
intensity and their dependent and independent relation to
disease severity are scarce in patients with COPD.
The purpose of this study was therefore to evaluate
different aspects of accelerometer derived activity data in
a well-characterized cohort of COPD patients in order to
extrapolate reliable identifiers of disease severity. We
suspect that not only the total activity volume is crucial in
terms of disease severity, but also the intensity with which
the activity is performed is a key outcome parameter.
Methods
Setting and study population
This prospective cohort study assessed daily physical
activity in COPD patients recruited in the “PredictingEffects and Risk Factors in Exacerbations of Chronic
obstructive pulmonary disease” (PROMISE) study.20 Data
from 107 patients included in the stable state at the Clinic
of Pulmonary Medicine of the University Hospital Basel,
Switzerland, between November 2008 and March 2010 were
analyzed. In brief, one of the primary end-points of the
study was to explore predictors that might identify recur-
rence and poor outcome during and outside exacerbations.
To be eligible for the study, patients had to be diagnosed
with COPD on the basis of clinical history, physical exami-
nation, and to meet post-bronchodilator spirometric
criteria for COPD Stage IIeIV according to the GOLD
guidelines at inclusion. Spirometry was performed by
trained lung function technicians according to American
Thoracic Guidelines at inclusion.12 Immunocompromised
patients, patients with cystic fibrosis, active pulmonary
tuberculosis or infiltrates on chest radiographs upon
presentation were excluded from the evaluation.
Regular follow-up visits were scheduled every 6 months
and unscheduled visits at exacerbation and at recovery
from exacerbation (after 4 weeks) were provided after
inclusion. Both the baseline visit and follow-up assessments
included detailed medical history, such as smoking status,
current medication, duration of disease, co-morbidities,
physical examination, quality of life questionnaires (SF-
36),21 Saint Georges Respiratory Questionnaire (SGRQ),22
Modified Medical Research Council Dyspnea Scale (MMRC),
spirometry, chest X-ray, 6-min walking test and
accelerometry.
The 6-min walking test was conducted in an enclosed
corridor on a measured course that was 40 m in length
according to the ATS guidelines. The course was marked
every 5 m, and subjects were instructed to walk from one
end to the other end, covering as much distance as possible
during the 6 min. Patients were verbally encouraged and
remaining time was called out after every elapsed minute.
Subjects were allowed to rest if needed. The BODE index
was computed based on a point value system including the
following variables: FEV1 % of predicted, distance walked in
the 6 min walk test in meters, MMRC dyspnea scale (IeIV)
and body mass index (h2/w), as previously described.23
Spontaneously expectorated sputum samples were
obtained and examined using standard techniques.24 Daily
activity monitoring by means of accelerometry was moni-
tored over eight days at the stable state of the disease
starting at scheduled visits. The study was carried out
according to the principles of the Declaration of Helsinki
and approved by our local ethics committee (Ethic
Commission Beider Basel EKBB 295/07). Written informed
consent was obtained from all participating patients.
Sample size calculation
This PROMISE study defines rather several scientific goals
instead of a single primary end-point.20 This approach is
1848 M. Jehn et al.believed to optimize information extraction, thereby
unrestricting data analysis in the context of a non-
interventional, longitudinal study. Power calculation was
based on the conservative assumption of a 20% recurrence
rate of acute exacerbation requiring hospitalization and/or
death within two-year follow-up. Thus, the inclusion of 600
patients is expected to result in 120 patients developing
a major clinical end-point during the study period. The
sample size is expected to allow subgroup comparisons and
analysis for clinically significant clinical outcomes. The
analysis of physical activity in a subgroup of the study
population was a pre-defined secondary end-point of the
protocol. Subgroup analysis, however, was not based on
a power calculation.
Accelerometer activity monitoring
Patients were handed the accelerometer (Aipermon
GmbH, Germany) during a schedule visit and instructed to
wear it whilst going about their daily business. The device
was attached to the patient’s belt and positioned above the
left hip. Patients were encouraged to wear the device
continuously during normal waking hours for eight consec-
utive days. The accelerometer was to be attached upon
rising in the morning and only to be taken off for showering,
bathing and sleeping. The first and last day were excluded
from the analysis. Therefore only six consecutive days were
included in the statistical analysis (a day started at 24.00
o’clock and ended at 24.00 o’clock the same day). All
device settings were pre-programmed for each patient
upon receiving it and the device was switched on
throughout the entire measurement period to keep patient
handling of the accelerometer to a minimum. Upon return,
the data were copied onto a PC, and its contents were
viewed via ActiCoach MPAT2Viewer, Aipermon. Wearing
time included min/day spent passively (PAS: sitting),
actively (ACT: movement, but not walking), walking (WLK:
0e5 km/h) and fast walking (FWLK: >5 km/h). These were
computed and analyzed. Walking speeds from 0 to 80 m/
min were detected as Walking and walking speeds from 83
to 115 m/min were detected as Fast Walking. Speeds above
115 m/min were considered Sportive at which point walking
would turn into jogging in most individuals. The thresholds
used to classify walking speeds are set forth by the manu-
facturer based on walking behavior in healthy individuals.
Non-wearing time was indicated by the device as “resting
mode”. Walking and fast walking times were added to
a total walking time (TWT). Activity modes and acceler-
ometer detection accuracy were extensively validated and
detailed results are reported elsewhere.25 In summary, the
device was able to accurately detect steps to 99% at
walking speeds ranging as low as 20 m/min onwards.
Data analysis
Statistical analysis was done using SPSS software (version
17.0, SPSS Inc.). Data were descriptively analyzed reporting
mean standard deviation (SD) for quantitative measure-
ments and percentages for frequencies. Bivariate correla-
tions of non-parametric variables were investigated using
SpearmaneRho correlation coefficient (R). Statisticalcomparisons between two unrelated measurements were
assessed by one-way ANOVA for comparison across GOLD
stages. In all data analyses, P-values less than 0.05 were
considered as statistically significant. A multivariable
logistic regression model was applied with BODE index 6
as the dependent variable. Statistically significant inde-
pendent predictors of this model were evaluated. Receiver
operating characteristic (ROC) analyses were performed to
determine the most reliable cut-off value in terms of
correct classification of patients with advanced stages of
COPD (BODE index 6) based on the parameter TWT and
FWLK (maximizing sum of sensitivity and specificity). The
area under the ROC-curve (AUC) was reported to assess
overall diagnostic performance of potential explanatory
variables (TWT and FWLK). Ninety-five percent confidence
intervals were reported for AUCs indicating statistically
significant diagnostic capability if the critical value of 0.5 is
not included. Statistically significant independent predic-
tors of this model were evaluated.
Results
Patient characteristics
A total of 107 patients were included in the study. Demo-
graphics of the study population are depicted in Table 1
(co-morbidities and medication use is depicted in Table 1
continued which is presented in the Online Supplement
only). Mean age of patient population was 65.3 10.8
years and 70% were men. Most patients were taking a long
acting anticholinergic agent (79%) and a combination of
LABA/ICS 82 (77%).
Activity data
The overall mean wearing time of the accelerometer was
10.9 2.8 h/day (Table 2). The overall mean non-wearing
time of the accelerometer was 13.1 2.8 h/day. There
was no statistical difference in min/day spent PAS or ACT,
however, there was a statistically significant difference
(P< 0.01) in WLK, FWLK, TWT, distance, steps per day and
kcal between GOLD II, III and IV. All significant correlations
between activity measures and clinical parameters are lis-
ted in Table 3.
To analyse the prognostic ability of accelerometer
derived activity parameters in terms of probability of poor
prognosis, a multivariable logistic regression analysis was
performed with BODE index 6 as the dependent variable,
age (years), PAS, ACT, FWLK, and TWT as covariates. Based
on this model, TWT (min/day) and FWLK (min/day) were
the only significant predictors of BODE index 6 (TWT:
PZ 0.029 and FLWK: PZ 0.040, respectively) Table 4
(Online Supplement only). ROC analysis was performed to
determine the best cut-off values for discriminating
patients into BODE index 6 based on these parameters.
The corresponding AUC-value with 95% CI for the parameter
TWT was 0.80 (95% CI: 0.70e0.90) and the AUC-value with
95% CI for the parameter FWLK was 0.87 (95% CI:
0.81e0.94). ROC analyses showed the optimal cut-off value
for TWT determined by Youden’s index being 33.3 min/day
with sensitivity of 86% and specificity of 70% and the
Table 1 Characteristics of patient population; data is presented as mean SD; overall group comparison by ANOVA; post hoc
group differences were tested by t-test with statistical significance set at P< 0.05. BMIZ body mass index; HRZ heart rate;
FEV1Z forced expiratory volume in one minute; FVCZ forced vital capacity; MMRCZmodified medical research council
dyspnea scale; 6MWTZ 6-minute walk test; SGRQZ St. Georges respiratory questionnaire.
GOLD II III IV Total P-value
N 31 51 25 107
Gender (male/female) 22/9 35/16 19/6 76/31 0.32
Age (years) 61.8 14.1 66.4 9.2 67.4 8.7 65.3 10.8 0.17
BMI (kg/m2) 27.5 5.8 26.7 6.02 23.7 4.9 26.2 5.8 0.02
Resting HR (beats/min) 77.7 11.8 79.0 12.8 83.4 11.7 79.6 12.3 0.19
Breathing rate 15.4 3.2 16.2 3.3 16.5 3.1 16.0 3.2 0.39
PaO2 saturation 95.4 1.2 94.3 2.6 93.6 2.5 94.6 2.4 0.14
FEV1 (L) 1.7 0.43 1.1 0.30 0.59 0.13 1.18 0.51 <0.0001
FEV1% 59.8 11.2 47.9 10.3 22.9 3.9 43.4 14.5 <0.0001
FVC% 57.7 11.2 47.8 10.3 33.5 9.5 47.7 13.4 <0.0001
BODE index 2.3 1.1 4.5 1.8 6.7 2.0 4.4 2.3 <0.0001
MMRC dyspnea scale 2.3 0.7 2.8 0.9 3.12 0.9 2.7 0.9 0.002
Current or former smoker 31 (100%) 51 (100%) 25 (100%) 107
6MWT (distance in meters) 441 73.4 388 113 320 127 387 115 0.001
6MWT HRmax 117 17.0 113 19.2 121 14.2 116 17.7 0.09
SGRQ total score 33.1 20.9 38.8 15.3 46.9 16.5 39.2 17.7 0.01
Charlson score (age adjusted) 4.33 2.56 4.63 2.94 4.40 2.31 4.49 2.67 0.87
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with sensitivity of 93% and specificity of 76% (Fig. 1).
Fig. 2 depicts the probability of patients with BODE
index 6 based on walking intensity and in relation to age
categorized by median age, i.e. NZ 50%, patients 70 and
patients< 70.Discussion
The main finding of this study is that accelerometer derived
walking time in terms of volume (min/day) and intensity is
significant and independent predictor of disease severity in
patients with COPD. Daily walking time and intensity can be
used to predict the probability of poor prognosis in patients
with COPD, i.e. BODE index 6 with corresponding optimal
cut-off values of 33 min/day for total walking time and
0.1 min/day for fast walking time. This information hasTable 2 Accelerometer activity data of patient population; d
ANOVA; post hoc group differences were tested by t-test with sta
Activity data (accelerometer)
GOLD II III
N 31 51
Passive (min/day) 430 157 441 1
Active (min/day) 138 57 130 6
Walk (min/day) 60.7 29.5 49.2 2
Fast walk (min/day) 3.9 7.9 2.7 5
Total walk (min/day) 64.0 33.2 52.0 2
Distance (meters/day) 3477 1968 2803 1
Steps (per day) 5075 2753 4318 2
kcal/day 396 183 361 1
Wearing time (h/day) 12.0 3.3 10.6 2
Non-wearing time (h/day) 13.00 3.4 13.4 2potential clinical perspective in terms of long-term patient
monitoring and screening due to its simplicity and appli-
cability to patients’ daily practical routine and coping
abilities.
Although total steps per day were also indicative of
functional exercise capacity and COPD severity, walking
time and intensity showed the strongest association with
both parameters. Activity data demonstrated that daily
walking activity, in particular walking intensity, is severely
impeded in patients with severe COPD and/or likelihood of
poor prognosis. This is most likely due to severe breath-
lessness patients experience in daily life even during simple
habitual activities such as walking around the house and/or
at the supermarket. In patients with poor prognosis (BODE
index 6), total daily walking times were accumulated
throughout the day by short intermittent walking spurts
(ca. 5 min) as opposed to single continuous segments
(30 min). This suggests a marked impairment in functionalata is presented as mean SD; overall group comparison by
tistical significance set at P< 0.05.
IV Total P-value
25 107
21 504 139 453 138 0.12
3 134 69.7 133 63 0.80
4.5 43.2 28.5 51.0 27.5 0.031
.03 0.3 0.77 2.4 5.6 0.001
5.5 43.5 28.8 53.5 29.5 0.021
562 2114 1545 2837 1741 0.011
272 3189 2238 4273 2486 0.013
81 264 157 348 181 0.020
.6 11.3 2.8 10.9 2.8 0.34
.4 12.7 2.9 13.1 2.8 0.51
Table 3 Significant bivariate correlations (R) of non-parametric variables using SpearmaneRho correlation coefficient R;
statistical significance set at P< 0.05. FWLKZ fast walk (min/day); TWTZ total walking time (min/day); SGRQZ St. Georges
respiratory questionnaire; MMRCZmodified medical research council dyspnea scale.
FLWK P-value TWT P-value Steps/day P-value
GOLD stage 0.35 <0.0001 0.27 <0.0001 0.28 <0.0001
BODE index 0.58 <0.0001 0.50 <0.0001 0.49 <0.0001
MMRC dyspnea scale 0.65 <0.0001 0.54 <0.0001 0.54 <0.0001
SGRQ score 0.39 <0.0001 0.26 <0.0001 0.25 <0.0001
6-min walk distance þ0.62 <0.0001 þ0.50 <0.0001 þ0.51 <0.0001
1850 M. Jehn et al.exercise capacity, albeit allowing patients to cope with
basic tasks, but generally making it impossible to engage in
recreational walking activities in terms of exercise.
In this study, a marked decrease in walking times and
intensity can already be seen in the early stages COPD such
as GOLD stage II patients. This is in accordance with findings
presented by Troosters et al.6 In fact, when comparing
GOLD stage II patients in our present study with previous
data we obtained in patients with moderate to severe heart
failure (NYHA III),27 GOLD II patients reached far lower daily
walking times (TWT: 64.0 33.2 min/day; FWLK
3.92 7.9 min/day; mean age: 61.8 14.1 years)
compared to NYHA III heart failure patients (TWT:
76.8 22.5 min/day; FWLK: 6.6 6.1 min/day; mean age:
58.1 14.8 years). In comparison, similar age control
subjects with normal exercise capacities showed much
higher daily walking times (TWT: 160.6 35.8 min/day;
FWLK: 30.7 22.4 min/day; mean age: 69.9 4.9 years).27
A moderate interaction between age, total walking time
and intensity could be observed in our study population,
albeit not significant. This might be due to the demo-
graphics of our study cohort and the fact that physical
activity generally decreases with increasing age in most
individuals independent of chronic diseases development.Figure 1 Roc-curve with corresponding AUC-value with 95%
CI for TWT was 0.80 (95% CI: 0.70e0.90) and 0.87 (95% CI:
0.81e0.94) for FWLK. The corresponding optimal cut-off value
for TWT was 33.3 min/day (sensitivity: 86%; specificity 70%)
and FWLK was 0.10 min/day (sensitivity: 93%; specificity 76%).In addition, disease severity in COPD typically manifests
itself with increasing age.26
The association between physical activity and disease
severity has been illustrated by previous investiga-
tors,7,14,28,29 although our study is more detailed in its
analysis. Moy et al. were able to demonstrate that higher
amounts of daily physical activities in a small cohort of
individuals with COPD were associated with higher FEV1 %
predicted and lower BODE index.14 Controversially, other
investigators have shown only weak correlations with lung
parameters, particularly the degree of airway obstruction,
and physical inactivity.7,19 Seemingly, Watz and
colleagues29 were able to link physical inactivity to higher
values of systemic inflammation markers and concomitant
co-morbidities such as left ventricular dysfunction.29 We
also found that the amount of physical inactivity (passive
time) increased with disease severity, however, could not
find any statistically significant predictive strength in terms
of probability of poor prognosis for this parameter. Here
too, an interaction with age could be extrapolated for this
observation as both physical inactivity and disease severity
increase with age.
Strengths and weaknesses of the study
The strengths of this paper include the detailed analysis of
daily physical activity in a well-characterized cohort of
COPD patients. Our findings could demonstrate that not
only the amount of daily physical activity per se, but the
intensity with which this habitual activity is performedFigure 2 Scatter plot illustrating the probability of patients
with BODE index 6 based on walking intensity (min/day
FWLK) and in relation to median age, i.e. NZ 50% of study
population (age 70 or age< 70 years).
Association of daily physical activity volume and intensity with COPD severity 1851seems important in determining functional capacity and
disease severity. This is an interesting new aspect, albeit
has to be prospectively evaluated and its clinical relevance
needs to be studied. Nevertheless, this new parameter
opens interesting new research avenues regarding the use
of accelerometer monitoring in COPD patients in order to
explore possible advantages to currently used parameters
such as 6-min walk test and VO2peak in reflecting clinical
prognosis. Such advantages could include continuous
patient monitoring in a real life setting, lower hospital
based resource requirements such as space and time limi-
tations and need for medically trained personal.
There are several limitations to this study. As mentioned
above, these findings must be confirmed in a prospective
study design to demonstrate a clear connection with clin-
ical prognosis. Moreover, the practicability of using activity
monitoring needs to be assessed in a clinical service
oriented setting as opposed to a research setting. Our study
population is limited in size and did not include any
patients at early stage of COPD (GOLD I) and/or control
subjects. In addition, there was no separate power calcu-
lation performed for this subgroup analysis. Lack of power
could therefore explain some non-significant relationships
presented in our study results. Nevertheless, statistical
power is provided in the confidence intervals of the ROC
analysis presented in our data analysis underlining the
validity of the findings presented in this study.
In conclusion, we could show that daily walking time and
intensity are closely linked to functional capacity and
disease severity in patients with COPD and can be used to
predict the probability of poor prognosis (BODE index 6).
This information might facilitate long-term patient
screening and continuous monitoring, thereby optimizing
long-term chronic disease management.Supplementary information
Supplementary information associated with this article
can be found in the online version at doi:10.1016/j.
rmed.2011.07.003.
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